FREQUENTLY ASKED QUESTIONS
What is the active ingredient in HALOG®?
The active ingredient in HALOG® is halcinonide, 0.1%, which is a corticosteroid.1,2
What are corticosteroid-responsive dermatoses (CRD)?
Corticosteroid-responsive dermatoses (CRD) are skin conditions that can be treated with corticosteroid medication. Examples of corticosteroid-responsive dermatoses (CRD) are plaque psoriasis, eczema, and atopic dermatitis. Topical corticosteroids (steroids) are one of the most commonly used treatments for reducing swelling or redness associated with corticosteroid-responsive dermatoses (CRD).3-5
How does halcinonide, 0.1% work?
Halcinonide, 0.1% acts quickly to relieve symptoms and stays within the skin over time for sustained relief.1,6
How do I know which formulation of HALOG® is right for me?
Each formulation has the same amount of halcinonide, 0.1%. HALOG® Solution is easy to use on the scalp or hair-bearing areas while HALOG® Cream and HALOG® Ointment can be easily spread on any dry, thick plaques or large body surface areas.1,2,6-9
How can I save on my HALOG® prescription?
Learn how you can pay less for your HALOG® prescriptions here.
How should I use HALOG® Solution?
Apply HALOG® Solution to the affected area 2 to 3 times daily.2
How should I store HALOG® Solution?
HALOG® Solution should be stored at room temperature; avoid freezing and temperatures above 104°F.2
How quickly does HALOG® Solution work?
HALOG® Solution has proven results in as little as two weeks.7 If you do not see improvement, consult your doctor.
How should I use HALOG® Ointment?
Apply a thin layer to the affected area 2 to 3 times daily.1
How should I store HALOG® Ointment?
HALOG® Ointment should be stored at room temperature, do not place in excessive heat.1
How should I use HALOG® Cream?
Apply to the affected area 2 to 3 times daily. Rub in gently.1
How should I store HALOG® Cream?
HALOG® Cream should be stored at room temperature, do not place in excessive heat.1
How quickly does HALOG® Cream work?
In two clinical studies, patients reported greater improvement from using HALOG® compared to fluocinonide cream 0.05% after 2 and 3 weeks of treatment.10,11
References: 1. HALOG® Cream and Ointment [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018. 2. HALOG® Solution [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2019. 3. National Psoriasis Foundation. About Psoriasis. https://www.psoriasis.org/about-psoriasis. Updated March 8, 2020. Accessed May 4, 2020. 4. National Eczema Association. Nationaleczema.org. https://nationaleczema.org/eczema/types-of-eczema/. Accessed June 8, 2020. 5. National Psoriasis Foundation. Psoriasis.org. https://www.psoriasis.org/sites/default/files/topicals_booklet_3.pdf. Accessed June 8, 2020. 6. Draelos ZD. A demonstration of the biphasic release characteristics of halcinonide 0.1% ointment. Poster presented at: 37th Annual Fall Clinical Dermatology Conference; October 18-21, 2018; Las Vegas, Nevada. 7. Lepaw MI. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis. 1978;21(4):571-573. 8. Greenberg RG, Fowler J Jr. Biphasic release halcinonide provides immediate and sustained class 2 topical corticosteroid activity. Poster presented at: Winter Clinical Dermatology Meeting; January 14-19, 2012; Lahaina, Hawaii. 9. Thau P, Fox C. A new procedure for the preparation of polyethylene-mineral oil gels. J Soc Cosmet Chem. 1965;16:359-363. 10. Close JE. Double-blind comparison of topical halcinonide and fluocinonide in the treatment of psoriasis. Int J Dermatol. 1976;15(7):534-537. 11. Sudilovsky A, Clewe TH. Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eczematous dermatoses. J Clin Pharmacol. 1975;15(1112):779-784.
INDICATIONS AND USAGE
HALOG® Solution (Halcinonide Topical Solution, USP) 0.1%, HALOG (Halcinonide Cream, USP) 0.1% and HALOG (Halcinonide OINTMENT, USP) 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information of respective products.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.